RNS Number: 8116C

Advanced Medical Solutions Grp PLC

31 March 2025

31 March 2025

Advanced Medical Solutions Group plc

("AMS", the "Company" or the "Group")

Directorate Change

Susan Searle Appointed as an Independent Non-Executive Director

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, is pleased to announce that our search for an additional Independent Non-Executive Director has successfully concluded and that Susan Searle has been appointed as a Non-Executive Director with immediate effect.

Susan has extensive experience on public and private company boards in a number of sectors, including healthcare. She is currently a Non-Executive Director of Gooch & Housego plc, where she is Chair of the Remuneration and Sustainability Committees, as well as being a Non-Executive of Bibby Line Group Limited and Chair of Greenback Recycling Technologies Limited. She has recently stepped down from QinetiQ plc where she was a Non-Executive Director and Remuneration Committee Chair, having served three full terms.

Susan was formerly Non-Executive Senior Independent Director and Remuneration Chair of Horizon Discovery plc and Benchmark Holdings Plc, both technology businesses. She also chaired two listed investment businesses - Mercia Asset Management plc and Schroders UK Public Private Trust plc, and was a founder of Touchstone Innovations plc, where she served as its CEO. She holds an MA in Chemistry from Oxford University.

Grahame Cook, Chair of AMS, said: "I am very pleased to welcome Susan to the Board of AMS. She has a wealth of Board experience with growth companies, including healthcare companies. She will be an extremely valuable addition to our Board."

Susan Searle commented: "I have followed AMS progress over the last few years and am excited to be joining the Board as the company continues its growth journey."

Susan will immediately join the Audit, Nomination and Remuneration Committees and be appointed as the Senior Independent Non-Executive Director. The composition of each of the Board Committees from 31 March 2025 is therefore confirmed as follows:

Board Committee	Membership
Audit Committee	Grahame Cook (Chair)
	Douglas Le Fort
	Susan Searle
Nomination Committee	Grahame Cook (Chair)
	Douglas Le Fort
	Susan Searle
Remuneration Committee	Douglas Le Fort (Chair)
	Grahame Cook
	Susan Searle

The following information is disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies:

Susan Searle (aged 61 years) holds or has held Directorships and partnerships in the five years preceding her appointment at AMS as follows:

Current Directorships	Previous Directorships
Bibby Line Group Limited	QinetiQ Group plc
Gooch & Housego plc	Benchmark Holdings plc
Greenback Recycling Technologies Limited	Horizon Discovery plc
	Schroders UK Public Private Trust plc

No further information in connection with her appointment is required to be disclosed under Schedule Two, paragraph (g) of the AIM Rules for Companies.

The Board is pleased to further announce that the search for an additional Non-Executive Director, who will be

appointed as Audit Committee Chair, is also underway and a further announcement will be made in the due course.

- End -

For further information, please visit www.admedsol.com or contact:

Advanced Medical Solutions Group plc Tel: +44 (0) 1606 545508

Chris Meredith, Chief Executive Officer Eddie Johnson, Chief Financial Officer Michael King, Investor Relations

ICR HealthcareTel: +44 (0) 20 3709 5700Mary-Jane Elliott / Lucy FeatherstoneAMS@icrhealthcare.com

Investec Bank PLC (NOMAD & Broker) Tel: +44 (0) 20 7597 5970

Gary Clarence / David Anderson

About Advanced Medical Solutions Group plc - see www.admedsol.com

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix&®, LIQUIFIX™, Peters Surgical, Ifabond, Vitalitec and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made seven acquisitions: Sealantis, an Israeli developer of innovative internal sealants, Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business, Connexicon, an Irish tissue adhesives specialist, Syntacoll, a German specialist in collagen-based absorbable surgical implants and Peters Surgical, a global provider of specialty surgical sutures, mechanical haemostasis and internal cyanoacrylate devices.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, Thailand, India, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, Austria, France, Poland, Benelux, India, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 1,500 employees. For more information, please see www.admedsol.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAWPUCAWUPAGQU